"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 1 | 2 |
| 2001 | 3 | 0 | 3 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 3 | 4 |
| 2005 | 2 | 5 | 7 |
| 2006 | 0 | 2 | 2 |
| 2007 | 2 | 3 | 5 |
| 2008 | 6 | 5 | 11 |
| 2009 | 2 | 4 | 6 |
| 2010 | 4 | 0 | 4 |
| 2011 | 4 | 2 | 6 |
| 2012 | 5 | 2 | 7 |
| 2013 | 4 | 4 | 8 |
| 2014 | 5 | 3 | 8 |
| 2015 | 5 | 8 | 13 |
| 2016 | 4 | 5 | 9 |
| 2017 | 3 | 4 | 7 |
| 2018 | 5 | 7 | 12 |
| 2019 | 3 | 5 | 8 |
| 2020 | 3 | 3 | 6 |
| 2021 | 5 | 4 | 9 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 5 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e600-e606.
-
MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb; 21(3):303-311.
-
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024 Dec 06; 29(12):1032-1043.
-
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid. 2025 Jan; 35(1):6-17.
-
Real-world quality-of-life of patients with HR+/HER2-?advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat. 2025 Feb; 209(3):613-627.
-
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma. J Immunother Cancer. 2024 Oct 30; 12(10).
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct; 8:e2400477.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
-
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.
-
A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. J Comp Eff Res. 2024 Oct; 13(10):e240111.